COVID-19 outbreak was first identified in Wuhan, China and spread rapidly throughout the world. COVID-19 can cause fatal comorbidities, especially ARDS. This observational analytic study analyse the association between the dose of CoronaVac vaccination and the severity of ARDS in the Province of NTB General Hospital with a cross-sectional method involving confirmed COVID-19 patients aged 18-59 years whose blood were analysed in the isolation ICU at the Province of NTB General Hospital in the period of March 2021 – March 2022. The data was taken from the subjects’ medical records by the consecutive sampling technique and analysed by Spearman test. Total of 51 subject, the male subject was 52.9% and the mean age was 47.64 years. Most subjects had not received vaccination (78,4%), whereas subjects had received the first dose of vaccine (13.7%) and subjects had received the second dose of vaccine (7.8%). More subjects presented with dyspnea (86.3%), cough (80.4%), and fever (60.8%). Hypertension and diabetes mellitus were the main comorbidities (13.7%). Outcomes in this study included dead (47.1%), self-isolated (35.3%), and recovered (17.6%). The mean value of the PaO2/FiO2 ratio is 127.21. The doses of CoronaVac vaccination has no significant association with the ARDS severity in subjects who unvaccinated (p=0.93), had received the first dose of vaccine (p=0 .47) or had received the second dose of vaccine (p=0.43) in COVID-19 patients treated in the ICU isolation at the Province of NTB General Hospital.